Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027

Arcturus Therapeutics Holdings Inc.

FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).
Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).
Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.
Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.
New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2023 results: revenue $34.0 million.

Period: the three months ended December 31, 2023
Revenue: $34.0 million
Result: reported results

Exact text from the filing

For the three months ended December 31, 2023, revenue recognized was $34.0 million compared with $160.3 million for the three months ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2023 results: revenue $169.9 million.

Period: the year ended December 31, 2023
Revenue: $169.9 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, we reported revenue of $169.9 million compared with $206.0 million for the year ended December 31, 2022.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-24-000335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.